United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - methenamine hippurate (unii: m329791l57) (methenamine - unii:j50oix95qv) - methenamine hippurate tablets are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. this drug should only be used after eradication of the infection by other appropriate antimicrobial agents. to reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate and other antibacterial drugs, methenamine hippurate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. methenamine hippurate tablets are contraindicated in patients with renal insufficiency, severe hepatic insufficiency, or severe dehydration. methenamine preparations should not be given to patients taking sulfonamides because some sulfonamides may form an insoluble precipitate with formaldehyde in the urine. clinical studies of methenamine hippurate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. methenamine hippurate tablets are contraindicated in patients with renal insufficiency and severe hepatic insufficiency (see contraindications).

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - methenamine hippurate, quantity: 1 g - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; magnesium stearate - supression or elimination of bacteriuria associated with chronic or recurrent infection of the urinary tract, especially when long term therapy is indicated.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - trimethobenzamide hydrochloride (unii: wdq5p1sx7q) (trimethobenzamide - unii:w2x096qy97) - tigan is indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. limitation of use: tigan is not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (cns) effects, and the risk of exacerbation of the underlying disease in pediatric patients with reye's syndrome or other hepatic impairment. tigan is contraindicated in patients with known hypersensitivity to trimethobenzamide [see adverse reactions (6)] . risk summary the limited available data with trimethobenzamide in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. no adverse developmental effect was observed in animal reproduction studies with administration of trimethobenzamide hydrochloride during organogenesis in pregnant rats at doses 0.16 and 0.8 times the recommended human dose (rhd) and in pregnant rabb

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - trimethobenzamide hydrochloride (unii: wdq5p1sx7q) (trimethobenzamide - unii:w2x096qy97) - tigan® is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. the injectable form of tigan® is contraindicated in pediatric patients and in patients with known hypersensitivity to trimethobenzamide.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; magnesium stearate - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: povidone; colloidal anhydrous silica; magnesium stearate - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; colloidal anhydrous silica - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; povidone; magnesium stearate - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

United States - English - NLM (National Library of Medicine)

henry schein, inc - trimethobenzamide hydrochloride (unii: wdq5p1sx7q) (trimethobenzamide - unii:w2x096qy97) - tigan ® is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. the injectable form of tigan® is contraindicated in pediatric patients and in patients with known hypersensitivity to trimethobenzamide. the injectable form of tigan® is contraindicated in pediatric patients and in patients with known hypersensitivity to trimethobenzamide.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - 1-aminomethanamide dihydrogen tetraoxosulfate; ethephon - aqueous concentrate - 1-aminomethanamide dihydrogen tetraoxosulfate amad active 873.0 g/l; ethephon organophosphorus active 275.0 g/l - growth regulator - cotton - acceleration of boll opening | defoliation of cotton plants | defoliation aid